Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erlene K Seymour

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Oncotarget|May 10, 2019
Rapid transitions in the standard of care for chronic lymphocytic leukemia (CLL)Erlene K Seymour
Journal of Oncology Practice|November 18, 2017
Challenges in the Clinical Application of the American Society of Clinical Oncology Value Framework: A Medicare Cost-Benefit Analysis in Chronic Lymphocytic LeukemiaErlene K Seymour, Charles A Schiffer, Jonas A de Souza
Cancer Journal (Sudbury, Mass.)|August 1, 2020
Incorporating Value-Based Care Into OncologyErlene K Seymour, Jonas A de Souza, A Mark Fendrick
Cancer|October 22, 2018
Real-world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysisErlene K Seymour, Julie J Ruterbusch, Jennifer L Beebe-Dimmer, et al.
JCO Oncology Practice|August 18, 2021
How to Effectively Decrease Patient Co-Payments of High-Cost Drugs Through Innovation: Lessons From the Karmanos Specialty PharmacyErlene K Seymour, Lucius Daniel, Eva Pointer, et al.
Cancer|September 17, 2019
Increasing incidence of Epstein-Barr virus-related nasopharyngeal carcinoma in the United StatesIlona Argirion, Katie R Zarins, Julie J Ruterbusch, et al.
Pharmacoeconomics - Open|April 22, 2025
A Systematic Literature Review of the Economic and Healthcare Resource Utilization Burden of Relapsed/Refractory Follicular LymphomaBijal Shah, Mei Xue, Wesley Furnback, et al.
Blood Advances|November 21, 2025
Real-World Comparative Effectiveness of Bruton Tyrosine Kinase Inhibitors in Relapsed/Refractory Mantle Cell LymphomaTycel J Phillips, Mengyang Di, Taavy Miller, et al.
Cancer|October 29, 2020
The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United StatesErlene K Seymour, Julie J Ruterbusch, Aaron N Winn, et al.
PEC Innovation|June 26, 2023
The DISCO App: A pilot test of a multi-level intervention to reduce the financial burden of cancer through improved cost communicationLauren M Hamel, David W Dougherty, Theresa A Hastert, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Oncotarget|May 10, 2019
Rapid transitions in the standard of care for chronic lymphocytic leukemia (CLL)Erlene K Seymour
Journal of Oncology Practice|November 18, 2017
Challenges in the Clinical Application of the American Society of Clinical Oncology Value Framework: A Medicare Cost-Benefit Analysis in Chronic Lymphocytic LeukemiaErlene K Seymour, Charles A Schiffer, Jonas A de Souza
Cancer Journal (Sudbury, Mass.)|August 1, 2020
Incorporating Value-Based Care Into OncologyErlene K Seymour, Jonas A de Souza, A Mark Fendrick
Cancer|October 22, 2018
Real-world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysisErlene K Seymour, Julie J Ruterbusch, Jennifer L Beebe-Dimmer, et al.
JCO Oncology Practice|August 18, 2021
How to Effectively Decrease Patient Co-Payments of High-Cost Drugs Through Innovation: Lessons From the Karmanos Specialty PharmacyErlene K Seymour, Lucius Daniel, Eva Pointer, et al.
Cancer|September 17, 2019
Increasing incidence of Epstein-Barr virus-related nasopharyngeal carcinoma in the United StatesIlona Argirion, Katie R Zarins, Julie J Ruterbusch, et al.
Pharmacoeconomics - Open|April 22, 2025
A Systematic Literature Review of the Economic and Healthcare Resource Utilization Burden of Relapsed/Refractory Follicular LymphomaBijal Shah, Mei Xue, Wesley Furnback, et al.
Blood Advances|November 21, 2025
Real-World Comparative Effectiveness of Bruton Tyrosine Kinase Inhibitors in Relapsed/Refractory Mantle Cell LymphomaTycel J Phillips, Mengyang Di, Taavy Miller, et al.
Cancer|October 29, 2020
The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United StatesErlene K Seymour, Julie J Ruterbusch, Aaron N Winn, et al.
PEC Innovation|June 26, 2023
The DISCO App: A pilot test of a multi-level intervention to reduce the financial burden of cancer through improved cost communicationLauren M Hamel, David W Dougherty, Theresa A Hastert, et al.
Pageof 2